102 related articles for article (PubMed ID: 23358408)
1. Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
Forrer F; Oechslin-Oberholzer C; Campana B; Maecke H; Mueller-Brand J; Lohri A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):544-50. PubMed ID: 23358408
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.
Forrer F; Oechslin-Oberholzer C; Campana B; Herrmann R; Maecke HR; Mueller-Brand J; Lohri A
J Nucl Med; 2013 Jul; 54(7):1045-52. PubMed ID: 23572496
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
Yadav MP; Singla S; Thakral P; Ballal S; Bal C
Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
[TBL] [Abstract][Full Text] [Related]
6. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
Thakral P; Singla S; Yadav MP; Vasisht A; Sharma A; Gupta SK; Bal CS; ; Malhotra A
Indian J Med Res; 2014 Apr; 139(4):544-54. PubMed ID: 24927340
[TBL] [Abstract][Full Text] [Related]
7. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
8. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
[TBL] [Abstract][Full Text] [Related]
11. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
Michel RB; Andrews PM; Rosario AV; Goldenberg DM; Mattes MJ
Nucl Med Biol; 2005 Apr; 32(3):269-78. PubMed ID: 15820762
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
13. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
[TBL] [Abstract][Full Text] [Related]
17. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
[TBL] [Abstract][Full Text] [Related]
18. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Forrer F; Chen J; Fani M; Powell P; Lohri A; Müller-Brand J; Moldenhauer G; Maecke HR
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1443-52. PubMed ID: 19350237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]